AbbVie and Genmab Highlight P-I/II (EPCORE NHL-2) Study Data of Epcoritamab to Treat R/R Follicular Lymphoma (FL) at ASH 2024
Shots:
- AbbVie reported data from Arm 2 (epcoritamab + rituximab & lenalidomide (R2) for r/r FL) of P-Ib/II (EPCORE NHL-2) assessing safety, tolerability, PK/PD, immunogenicity & efficacy of epcoritamab alone & combined with SoC therapies to treat B-NHL. Trial consists of 10 arms
- Study, in 111 patients at a median follow-up of over 2yrs., showed ORR of 96% & CRR of 87% with 89% of complete responders remaining in CR at 18mos., 88% were MRD negative, suggesting no detectable disease at 10-6 threshold
- Epcoritamab & R2 combination has been designated with the US FDA’s BTD to Treat r/r FL. The regimen is further being assessed under P-III (EPCORE FL-1) for the same indication
Ref: AbbVie | Image: AbbVie and Genmab
Related News:- AbbVie and Genmab Receive EC’s Conditional Marketing for Tepkinly (epcoritamab) to Treat Relapsed or Refractory Diffuse Large B-cell Lymphoma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
